These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3927035)

  • 1. [Study on the levels of anti-A, anti-B isoagglutinin titer in various kinds of concentrates for hemophilia treatment--with special regard to the manufacturing process of factor VIII concentrate].
    Tomita Y; Inagaki M; Taki M; Miura T; Saito N; Sato R; Meguro T; Yamada K
    Rinsho Ketsueki; 1985 Feb; 26(2):166-70. PubMed ID: 3927035
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemolysis caused by factor VIII concentrates.
    Orringer EP; Koury MJ; Blatt PM; Roberts HR
    Arch Intern Med; 1976 Sep; 136(9):1018-20. PubMed ID: 962445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of low plasma haptoglobin values found in hemophilia A patients on prophylactic treatment with factor VIII concentrates - a sign of hemolysis?
    Egberg N; Blombäck M
    Thromb Haemost; 1981 Aug; 46(2):554-7. PubMed ID: 6795743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of hepatitis B antigen and isoagglutinins in clinical concentrates of factor VIII and prothrombin complex.
    Wickerhauser M
    Dev Biol Stand; 1974; 27():172-7. PubMed ID: 4463121
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemophiliac with hemolytic anemia resulting from factor VIII concentrate.
    Soni NS; Patel AR; Vohra RM; Shah PC
    Acta Haematol; 1977; 58(5):294-7. PubMed ID: 413305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Severe serogenic hemolytic anemia caused by anti-D fraction in factor VIII concentrate].
    Schricker KT; Schrenk KH
    Thromb Diath Haemorrh; 1972 Jul; 27(3):523-8. PubMed ID: 4197045
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemolytic anemia due to anti-B in antihemophiliac factor concentrates.
    Ashenhurst JB; Langehennig PL; Seeler RA; Telfer MC
    J Pediatr; 1976 Feb; 88(2):257-8. PubMed ID: 1249687
    [No Abstract]   [Full Text] [Related]  

  • 8. [Case of hemolytic anemia following treatment with cryobulin].
    Pluta A; Kniaź M; Kowalewski J
    Wiad Lek; 1980 Apr; 33(7):555-7. PubMed ID: 6771920
    [No Abstract]   [Full Text] [Related]  

  • 9. Acquired hemolytic anemia and thrombocytopenia (Evans' syndrome) in hemophilia.
    Harris PJ; Kessler CM; Lessin LS
    N Engl J Med; 1983 Jul; 309(1):50. PubMed ID: 6406894
    [No Abstract]   [Full Text] [Related]  

  • 10. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin.
    Santagostino E; Gringeri A; Tagliavacca L; Mannucci PM
    Thromb Haemost; 1995 Aug; 74(2):619-21. PubMed ID: 8584995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent findings on hemophilia].
    Abe T; Kinoshita T
    Nihon Rinsho; 1981; 39(12):3647-56. PubMed ID: 6803031
    [No Abstract]   [Full Text] [Related]  

  • 13. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of haemophilia with factor VIII inhibitor by giving isoagglutinin-free factor VIII concentrate (author's transl)].
    Bartholomé K; Geiger H; Schimpf K
    Dtsch Med Wochenschr; 1976 Aug; 101(34):1252-4. PubMed ID: 947734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 16. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
    Ewenstein BM; Hoots WK; Lusher JM; DiMichele D; White GC; Adelman B; Nadeau K
    Haematologica; 2000 Oct; 85(10 Suppl):35-9. PubMed ID: 11187868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations.
    Rosati LA; Barnes B; Oberman HA; Penner JA
    Transfusion; 1970; 10(3):139-41. PubMed ID: 5422224
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hemolytic anemia caused by infusion of factor VIII concentrates--a case report of hemophilia A with intracranial hemorrhage].
    Fukazawa K; Okuyama T; Manabe H; Kanaya J
    Rinsho Ketsueki; 1983 Jul; 24(7):892-6. PubMed ID: 6415317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.